Efficacy of Vitex Agnus-castus BNO 1095 (20 mg) in Women With Primary Dysmenorrhea

Primary Dysmenorrhea Clinical Trial

Official title:

Efficacy of Vitex Agnus-castus BNO 1095 (20 mg) in Women With Primary Dysmenorrhea

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06211049
• Other study ID #: AgnoMed
• Secondary ID: 2023-503688-41-0
• Status: Recruiting
• Phase: Phase 3
• Start date: December 12, 2023
• Est. completion date: March 31, 2025

Study information

• Verified date: March 2024
• Source: Bionorica SE
• Contact: Kundeninfoservice
• Phone: +49918123190
• Email: info[@]bionorica.de
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this Phase III study, the herbal product Vitex agnus-castus BNO 1095 20 mg will be tested.

The sponsor would like to find out if treatment with Vitex agnus-castus BNO 1095 20 mg may improve the cramping pain before or during menstruation (primary dysmenorrhea) (without an organic cause) in women and if this treatment is safe. It is tested, if the pelvic pain and other symptoms during menstruation improve in patients who are treated with Vitex agnus-castus BNO 1095 20 mg and if therefore the standard treatments for primary dysmenorrhea, for example pain relief medications will not have to be increased.

The study has 2 treatment groups. Patients in one group will receive Vitex agnus-castus BNO 1095 20 mg, and patients in the other group will receive a placebo. Placebo tablets look like Vitex agnus-castus BNO 1095 20 mg tablets but have no active ingredient. Patients will be randomly assigned (like tossing a coin) to one of the 2 groups (this process is called randomization). The chance for the patients to receive Vitex agnus-castus BNO 1095 is 50%. Neither the patients nor the investigators know which product the patients are taking (this method is known as "double-blind").

Description:

This is a randomized, placebo-controlled, double-blind, multicenter, phase III clinical trial to investigate the efficacy and safety of investigational medicinal product (IMP) Vitex agnus-castus BNO 1095 20 mg in women with primary dysmenorrhea.

The clinical trial will be conducted in Austria, Czech Republic, Germany, Hungary, Poland and Sweden.

About 390 patients will be screened so that about 300 patients (150 patients per treatment group) will be randomized.

Vitex agnus-castus BNO 1095 20 mg is extracted from the fruits of the plant Vitex agnus-castus also called monk's pepper or chaste tree. Vitex agnus-castus BNO 1095 20 mg is currently marketed for the treatment of the premenstrual syndrome (PMS) which means repeated occurrence of physical, behavioral and psychological symptoms the days before the onset of menstruation, but it is not authorized for the treatment of primary dysmenorrhea.

The study has 2 treatment groups. Patients in one group will receive Vitex agnus-castus BNO 1095 20 mg, and patients in the other group will receive a placebo. Patients will be randomly assigned 1:1 to one of the 2 groups. The chance to receive Vitex agnus-castus BNO 1095 is 50%. The study is double blinded, neither the patients nor the investigators know which product the patients are taking.

The study will last about 7 months for each patient. There will be 5 visits at the study site, and in addition the patients will receive 3 phone calls from the study site. On average, each study site visit will take about 2 hours and each phone call about half an hour.

The trial will include 3 phases: a screening and run-in phase of up to 2 menstrual cycles, a treatment phase of 4 menstrual cycles and a follow-up phase of 1 menstrual cycle. The length of each phase depends on the length of women's menstrual cycle. If their menstrual cycle is 28 days, the screening and run-in phase will take up to 59 days (slightly more than 2 menstrual cycles), the treatment phase 113 days (about 4 menstrual cycles), and the follow-up phase 28 days (1 menstrual cycle).

The main objective of this study is to determine if primary dysmenorrhea improves in women treated with Vitex agnus-castus BNO 1095 20 mg compared to placebo over a treatment duration of 3 menstrual cycles (cramping windows of Cycles 3-5).

Vitex agnus-castus BNO 1095 20 mg or placebo tablets are taken orally (means by mouth) once a day during the treatment phase.

If a patient usually takes pain relief medication for primary dysmenorrhea, the patient is allowed to continue taking this pain relief medication during study participation.

The patients will complete the dysmenorrhea daily diary (DysDD) every day in the evening. Depending on her bleeding status, the diary includes questions about menstrual bleeding, pieces of sanitary protection used, severity of the worst pain or cramps in the pelvic area on a numerical rating scale (NRS), intake of pain relief medication, and impact on daily life in an electronic diary (handheld device).

Additionally, the dysmenorrhea associated symptoms nausea, vomiting, diarrhea, fatigue, weakness, fainting, and headache will be assessed by the patients on a NRS in the electronic diary on Days 1-3 of the menstrual cycle. Migraine will be assessed by the investigator at the clinical trial visits. The patient and investigator will assess the efficacy of treatment on a 5-point verbal rating scale at the end of treatment and at the end of the study (EoS).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: March 31, 2025
• Est. primary completion date: March 31, 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 49 Years

Eligibility

Inclusion Criteria:

1. Women aged 18-49 years who have the capacity for consenting

2. Patient has been informed of the nature, scope, and relevance of the clinical trial, voluntary agrees in participation and the trial provisions, and has duly signed the approved informed consent form (ICF)

3. Diagnosed primary dysmenorrhea

4. If patients take pain relief medication for primary dysmenorrhea, this medication should be taken unchanged with regard to application form and kind of medication including strength during the Screening as well as during the first three treatment cycles.

Note: Medication (drugs) for primary dysmenorrhea as mono- or combination therapy in form of tablets/capsules regularly used by the patient before Screening is allowed to be used as standard pain relief medication during the trial apart from non-medication methods. A complete list of allowed pain relief medication is attached to the protocol.

This medication should be taken by the patient at least for 1 cycle before Screening guaranteeing a stable intake of this medication in total for 3 cycles before randomization.

5. Patients with a regular menstrual cycle duration of =24 to =38 days

6. Patients agreeing to use one of the following contraception methods throughout the trial:

1. Bilateral tubal occlusion

2. Vasectomized partner (provided that the partner is the sole sexual partner of the woman and has received medical assessment of the surgical success)

3. Sexual abstinence Abstinence is only accepted as true abstinence when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods and withdrawal) is not an acceptable method of contraception

4. Male or female condom with or without spermicide

5. Cap, diaphragm, or sponge with spermicide

Exclusion Criteria:

A patient will not be eligible for inclusion if any of the following criteria applies:

1. Non-menstruating women

2. Clinically diagnosed secondary dysmenorrhea (e.g., fibroids, uterine adenomyosis, endometriosis, pelvic inflammation, ovarian pathologies, or other pelvic diseases)

3. Dysmenorrhea resulting from the use of an intrauterine device

4. Use of hormonal contraceptives (oral, intravaginal, transdermal, injectable, implantable), intrauterine device, or intrauterine hormone-releasing system within 6 months prior to the trial and not willing to waive it during the entire trial period

5. Any surgical treatments in the past (e.g., due to myoma) that may cause pain, adhesions or scarring in the lower abdomen Note: Further diagnostic examination (e.g., laparoscopy for differential diagnosis, exclusion of endometriosis) if deemed necessary by the investigator will be outside the trial protocol and reimbursement

6. Known or suspected gastrointestinal or urological conditions that may cause abdominal and/or pelvic pain, such as colitis, appendicitis, irritable bowel syndrome, cholelithiasis, interstitial cystitis, cystitis, urolithiasis, and other conditions that, according to the investigator's judgement, are not suitable for the trial

7. Known or suspected gynecological complaints e.g., premenstrual abdominal pain, deep dyspareunia, uterine fibroids and polyps, chronic pain (abdominal, urogenital), or backpain

8. Known instable diseases e.g., psychiatric, cardiovascular, or endocrine disorders

9. Body mass index <18.5 or >34.9 kg/m² at Screening

10. Positive gonorrhea, syphilis and/or chlamydia test at Screening

11. Current or past estrogen sensitive cancer or pituitary disorder that, in the investigator's opinion, would make the patient not suitable for the trial

12. Women who are breastfeeding, pregnant (positive pregnancy test at Screening), or planning to become pregnant during the trial

13. Fewer than 3 menstrual cycles before Screening following delivery, abortion, miscarriage, or lactation

14. Current severe physical or mental illness

15. Patient does not agree to avoid daily smoking

16. History of alcohol, drug, or medicine abuse within 1 year prior to Screening, or positive for drugs or medicines of abuse in the laboratory analysis performed at Screening

17. Patients with hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption

18. Hypersensitivity to Vitex agnus-castus, lactose or any of the excipients of the IMP or to any ingredients of the standard pain relief medication

19. Patients committed to an institution by virtue of an order issued either by the judicial or the administrative authorities

20. Employees of the sponsor or employees or relatives of the investigator

21. Legal incapacity or limited legal capacity

22. Patients not able to follow trial instructions or assessments or to participate in the trial for the whole duration of approximately 7 months or unable to understand written and verbal instruction, in particular regarding the risks and inconveniences that the patients will be exposed to during participation in the clinical trial

23. Participation in another interventional clinical trial during the last month before Screening

24. Use of Vitex agnus-castus containing preparation or product within the last 3 months before Screening

25. Current intake or intake within the last 4 weeks before Screening of dopamine agonists, dopamine antagonists, estrogens, or antiestrogens that would make the patient not suitable for the trial

Related Conditions & MeSH terms

• Dysmenorrhea
• Primary Dysmenorrhea

Intervention

Drug:
• Vitex agnus-castus BNO 1095 (20 mg)
1 tablet once daily for about 4 menstrual cycles (cramping windows of Cycles 3-6) (i.e.,113 days in case of a 28-day menstrual cycle).
• Placebo
1 tablet once daily for about 4 menstrual cycles (cramping windows of Cycles 3-6) (i.e.,113 days in case of a 28-day menstrual cycle).

Locations

Country	Name	City	State
Austria	Medizinische Universität Innsbruck, Department Frauenheilkunde, Universitätsklinik für Gynäkologische Endokrinologie und Reproduktionsmedizin	Innsbruck
Austria	Medizinische Universität Wien, Universitätsklinik für Frauenheilkunde, Klinische Abteilung für Gynäkologische Endokrinologie und Reproduktionsmedizin	Wien
Czechia	Centrum ambulantní gynekologie a primární péce s.r.o.	Brno Stred
Czechia	Fakultní nemocnice Brno, Gynekologickoporodnická Klinika, Centrum asistované reprodukce CAR 01 Brno	Brno Stred
Czechia	GYNEKOLOGIE CHEB s.r.o.	Cheb
Czechia	NEUMED gynekologická ambulance s.r.o	Olomouc
Czechia	Centrum gynekologické rehabilitace s.r.o	Písek
Czechia	MUDr. Martina Marešová Rosenbergová s.r.o.	Plzen
Czechia	Gyncare MUDr. Michael Švec s.r.o.	Plzen 2-Slovany
Germany	Praxis Dr. Noel	Aachen
Germany	Klinische Forschung Berlin-Mitte GmbH	Berlin
Germany	Frauenarztpraxis Dipl. med. Andrea Heweker, Praxis für Gynäkologie	Bernburg
Germany	Klinische Forschung Dresden GmbH	Dresden
Germany	Praxis Geseke	Geseke
Germany	Frauenarztpraxis Dr. Inka Kiesche	Halle
Germany	Frauenarzt-Praxis Dr. med. Klaus Peters	Hamburg
Germany	Klinische Forschung Hamburg GmbH	Hamburg
Germany	Klinische Forschung Hannover Mitte GmbH	Hannover
Germany	Praxis Dirk-Toralf Baerens	Ilsede
Germany	Klinische Forschung Karlsruhe GmbH	Karlsruhe
Germany	Klinische Forschung Schwerin GmbH	Schwerin
Germany	Frauenarzt in Stolberg - Wolfgang Clemens	Stolberg
Hungary	Clinexpert Kft.	Budapest
Hungary	Óbudai Egészségügyi Centrum Kft.	Budapest
Hungary	Zatik Med Kft.	Debrecen
Hungary	BKS Research Kft.	Hatvan
Hungary	AXON Kereskedelmi Es Szolgaltato Kft.	Kecskemét
Hungary	IPR Hungary Kft.	Miskolc
Poland	Centrum Medyczne Mikolowska dr Adam Sipinski	Katowice
Poland	Silmedic Sp. z o.o.	Katowice
Poland	Centra Medyczne Medyceusz Sp. z o.o.	Lódz
Poland	Nzoz Profi-Med	Lublin
Poland	Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych i Administracji, Klinika Poloznictwa, Chorób Kobiecych i Ginekologii Onkologicznej	Warszawa
Sweden	Danderyds Sjukhus AB (Hospital), Clinical Trials Unit, Dept of obstetrics and gynecology	Danderyd
Sweden	Karolinska University Hospital, WHO-centre	Stockholm
Sweden	Umeå University, Dep. of Clinical Sciences, Obstetrics and Gynecology	Umeå

Sponsors (2)

Lead Sponsor	Collaborator
Bionorica SE	FGK Clinical Research GmbH

Countries where clinical trial is conducted

Austria,  Czechia,  Germany,  Hungary,  Poland,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Proportion of patients with treatment-emergent adverse events (TEAEs), TEAEs related to the IMP, serious TEAEs related to the IMP, and TEAEs leading to premature discontinuation of the IMP	The number of patients with TEAEs, TEAEs related to the IMP, serious TEAEs related to the IMP and TEAEs leading to premature discontinuation of the IMP will be determined.	From Baseline (28 days prior to randomization) until Visit 5 (Day 141).
Other	Assessment of change in safety laboratory parameters analyzed from blood samples (hematology)	Proportion of participants with changes in hematology safety laboratory test results will be assessed. Hematology safety parameters which will be analyzed from patients' blood samples include: Platelets, hemoglobin, hematocrit, white blood cell count total and differential (neutrophils, lymphocytes, monocytes, eosinophils, basophils), red blood cell count, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC).	Change from Baseline (28 days prior to randomization) to Visit 4 (Day 113).
Other	Assessment of change in safety laboratory parameters analyzed from blood samples (biochemistry)	Proportion of participants with changes in safety laboratory test results will be assessed. Biochemistry safety parameters which will be analyzed from patients' blood samples include: Liver: aspartate aminotransferase, alanine aminotransferase, gammaglutamyl transferase, alkaline phosphatase, bilirubin total; Kidney: urea (blood urea nitrogen calculated), creatinine, uric acid, glomerular filtration rate (Cockcroft and Modification of Diet in Renal Disease [MDRD] or Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equation), creatine clearance (Cockcroft-Gault) Other: total protein, potassium, sodium, calcium, creatine phosphokinase, glucose, chloride, inorganic phosphorous, lactate dehydrogenase, triglycerides, cholesterol total, albumin.	Change from Baseline to (28 days prior to randomization) Visit 4 (Day 113).
Other	Assessment of change in vital signs: systolic and diastolic blood pressure	Number of participants with changes in systolic and diastolic blood pressure will be assessed.	Change from Baseline (28 days prior to randomization) to Visit 4 (Day 113).
Other	Assessment of change in vital signs: pulse	Number of participants with changes in pulse will be assessed.	Change from Baseline to (28 days prior to randomization) Visit 4 (Day 113).
Other	Assessment of change in vital signs: body temperature	Number of participants with changes in body temperature will be assessed.	Change from Baseline to (28 days prior to randomization) Visit 4 (Day 113).
Other	Assessment of change in vital signs: body height	Number of participants with changes in body height will be assessed.	Change from Baseline to (28 days prior to randomization) Visit 4 (Day 113).
Other	Assessment of change in vital signs: body weight	Number of participants with changes in body weight will be assessed.	Change from Baseline to (28 days prior to randomization) Visit 4 (Day 113).
Other	Assessment of change in physical examination of the genitourinary system: speculum examination	Number of participants with changes in speculum examination findings will be assessed.	Change from Baseline (28 days prior to randomization) to Visit 4 (Day 113).
Other	Assessment of change in physical examination of the genitourinary system: bimanual examination	Number of participants with changes in bimanual examination findings will be assessed.	Change from Baseline (28 days prior to randomization) to Visit 4 (Day 113).
Other	Assessment of change in physical examination: palpation of the breast	Number of participants with changes in palpation of the breast findings will be assessed.	Change from Baseline (28 days prior to randomization) to Visit 4 (Day 113).
Other	Assessment of investigator's and patient's tolerability using a 5-point verbal rating scale	The tolerability will be assessed by investigator and patient using a 5-point verbal rating scale: Very good = 0 (no side effects; no limitation of work and leisure activities due to side effects or adverse reactions); Good = 1 (hardly any side effects; hardly any limitation of work and leisure activities due to side effects or adverse reactions); Moderate = 2 (mild side effects; slight limitation of work and leisure activities due to side effects or adverse reactions); Poor = 3 (distinct side effects; distinct limitation of work and leisure activities due to side effects or adverse reactions); Very poor = 4 (severe side effects; work and leisure activities not possible due to side effects or adverse reactions).	Visits 4 (Day 113) and 5 (Day 141).
Other	Number of participants with absolute and relative changes in blood hormone concentrations	Absolute and relative changes from Baseline in blood hormone concentration will be analyzed using laboratory tests.	Changes from Baseline (28 days prior to randomization) to the Visits 2 (Day 57), 3 (Day 85) and 4 (Day 113).
Other	Assessment of change in blood cytokine concentrations	Absolute and relative changes from Baseline in cytokine concentration will be analyzed using Enzyme-linked Immunosorbent Assays (ELISA).	Change from Baseline (28 days prior to randomization) to Visit 4 (Day 113).
Other	Assessment of change in metabolome parameters (only for optional sub-study)	Absolute and relative changes from Baseline in metabolome parameters assessed in the optional sub-study will be analyzed.	Change from Baseline (28 days prior to randomization) to Visit 4 (Day 113).
Other	Assessment of change in lipidome parameters (only for optional sub-study)	Absolute and relative changes from Baseline in lipidome parameters assessed in the optional sub-study will be analyzed.	Change from Baseline (28 days prior to randomization) to Visit 4 (Day 113).
Other	Assessment of change in microbiome parameters (only for optional sub-study)	Absolute and relative changes from Baseline in microbiome parameters assessed in the optional sub-study will be analyzed.	Change from Baseline (28 days prior to randomization) to Visit 4 (Day 113).
Primary	Proportion of patients who respond to treatment defined as: a) a =3-point reduction in the peak pelvic pain score and b) no increase in the number of standard pain relief medication	Response to treatment will be determined by comparing the peak pelvic pain score (using an 11-point numeric rating scale (NRS, scale ranging from 0 (no symptom) to 10 (extreme severity of symptom) of the dysmenorrhea daily diary (DysDD) assessments) made during the cramping window of Cycle 5 with those made at Baseline and by comparing the assessments of number of tablets or capsules of standard pain relief medication taken during the cramping window of Cycle 5 with those taken at Baseline.	Change from Baseline (28 days prior to randomization) to the cramping window of Cycle No. 5 (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary	Proportion of patients who respond to treatment defined as: a) a =3-point reduction in the peak pelvic pain score and b) no increase in the number of standard pain relief medication in the cramping window of Cycles 3, 4, and 6 compared to Baseline	Response to treatment will be determined by comparing the peak pelvic pain score (using an 11-point numeric rating scale (NRS, scale ranging from 0 (no symptom) to 10 (extreme severity of symptom) of the dysmenorrhea daily diary (DysDD) assessments) made during the cramping window of Cycles No. 3, 4 and 6 with those made at Baseline and by comparing the assessments of number of tablets or capsules of standard pain relief medication taken during the cramping window of Cycles No. 3, 4 and 6 with those taken at Baseline.	Change from Baseline (28 days prior to randomization) to the cramping windows of Cycles No. 3, 4 and 6 (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary	Proportion of patients with a =3-point reduction in the peak pelvic pain score and a decrease in the number of standard pain relief medication	The =3-point reduction in the peak pelvic pain score using an 11-point numeric rating scale (NRS; scale ranging from 0 (no symptom) to 10 (extreme severity of symptom)) of the dysmenorrhea daily diary (DysDD) will be assessed and the amount of standard pain relief medication taken will be evaluated to investigate the efficacy of the study drug.	Change from Baseline (28 days prior to randomization) to the cramping windows of Cycles No. 3, 4, 5 and 6) (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary	Proportion of patients with a peak pelvic pain score of "0" or "1" and no use of standard pain relief medication	Peak pelvic pain score of "0" or "1" using an 11-point numeric rating scale (NRS; scale ranging from 0 (no symptom) to 10 (extreme severity of symptom)) of the dysmenorrhea daily diary (DysDD) and no use of standard pain relief medication during the cramping window of Cycles 3, 4, 5, and 6 will be evaluated.	At the cramping windows of Cycles No. 3, 4, 5 and 6) (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary	Assessment of change of peak pelvic pain score	The peak pelvic pain score will be assessed using an 11-point numeric rating scale (NRS, scale ranging from 0 (no symptom) to 10 (extreme severity of symptom)) of the dysmenorrhea daily diary (DysDD) assessments and compared to Baseline.	Change from Baseline (28 days prior to randomization) to the cramping windows of Cycles No. 3, 4, 5 and 6) (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary	Assessment of the sum of the pelvic pain scores	The pelvic pain scores assessed during the cramping windows (4 days) of Cycles 3, 4, and 5 (i.e., 12 assessments in total) using an 11-point numeric rating scale (NRS; scale ranging from 0 (no symptom) to 10 (extreme severity of symptom)) of the dysmenorrhea daily diary (DysDD) will be summed up.	At the cramping windows of Cycles No. 3, 4 and 5 (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary	Assessment of the change of the sum of the pelvic pain scores	The pelvic pain scores assessed during the cramping window using an 11-point numeric rating scale (NRS, scale ranging from 0 (no symptom) to 10 (extreme severity of symptom)) of the dysmenorrhea daily diary (DysDD) assessments will be summed up per cycle and compared to Baseline.	Change from Baseline (28 days prior to randomization) to the cramping windows of Cycles No. 3, 4, 5 and 6) (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary	Assessment of the change in the number of days with pelvic pain	The number of days with pelvic pain will be calculated as sum of the days with a pelvic pain above 0 on the 11-point numeric rating scale (NRS, scale ranging from 0 (no symptom) to 10 (extreme severity of symptom)) during the respective cramping window and compared to Baseline.	Change from Baseline (28 days prior to randomization) to the cramping windows of Cycles No. 3, 4, 5 and 6) (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary	Assessment of change in the number of standard pain relief medication taken	The number of standard pain relief medication will be calculated as sum of the tablets/capsules taken during the respective cramping window and compared to Baseline.	Change from Baseline (28 days prior to randomization) to the cramping windows of Cycles No. 3, 4, 5 and 6) (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary	Assessment of change in the number of days with use of standard pain relief medication	The number of days with use of standard pain relief medication will be calculated as sum of days with intake of standard pain relief medication during the respective cramping window and compared to Baseline.	Change from Baseline (28 days prior to randomization) to the cramping windows of Cycles No. 3, 4, 5 and 6) (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary	Proportion of patients with no use of standard pain relief medication	The number of patients who did not use any standard pain relief medication will be determined.; The analysis will be performed for all patients as well as for the subgroup of patients who took any standard pain relief medication during the cramping window of Cycle 5.	At the cramping window of Cycle No. 6 (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary	Assessment of change in the impact on the patient's daily life	The impact of pelvic pain or cramps on the patient's daily life including paid work, work around the home, or school work will be assessed on a 5-point scale being part of the dysmenorrhea daily diary (DysDD) assessments (0=not at all, 1=slightly, 2=moderately, 3=quite a bit, 4=extremely). The assessments made during each cramping window will be summed up.; The impact on physical activities, social or leisure activities, and sleep will be analyzed analogously. The missed time of paid work, work around the home, or school work will be summed up for the cramping window and tabulated by treatment group and cycle.	Change from Baseline (28 days prior to randomization) to the cramping windows of Cycles No. 3, 4, 5 and 6) (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary	Investigator's and patient's overall assessment of efficacy using a 5-point verbal rating scale	The treatment efficacy will be assessed by the investigator and the patient using a 5-point verbal rating scale with the following 5 categories: very good, good, moderate, poor, very poor.	Visits 4 (Day 85) and 5 (Day 113)
Secondary	Assessment of change in the intensity of menstrual bleeding	The intensity of the menstrual bleeding will be assessed on a 5-point scale (0=no bleeding, 1=very light bleeding or spotting, 2=light bleeding, 3=moderate bleeding, 4=heavy bleeding). The assessments made during each cramping window will be summed up.	Change from Baseline (28 days prior to randomization) to the cramping windows of Cycles No. 3, 4, 5 and 6) (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary	Assessment of change in the number of pieces of sanitary protection used	The number of pieces of sanitary protection used will be assessed on a 4-point scale (0=0, 1=1 piece, 2=2 pieces, 3=3 or more pieces). The assessments made during Day 1 to Day 3 of the cramping window will be summed up.	Change from Baseline (28 days prior to randomization) to the cramping windows of Cycles No. 3, 4, 5 and 6) (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary	Assessment of change in the severity of nausea, vomiting, diarrhea, fatigue, weakness, fainting, and headache on a numeric rating scale (NRS)	The analysis is based on the peak NRS score of days 1, 2, and 3 per cycle (11-point NRS scale ranging from 0 (no symptom) to 10 (extreme severity of symptom)).	Change from Baseline (28 days prior to randomization) to the Days 1-3 of Cycles No. 3, 4, 5 and 6 (each cycle is 28 days).
Secondary	Proportion of patients with migraine	The number of patients with migraine will be determined. The chance of patients having a migraine episode since the last clinical trial visit will be analyzed.	At Baseline (28 days prior to randomization) and Visits 0, 1, 2, 3, 4 and 5 (i.e., Days 1, 29, 57, 85, 113 and 141)
Secondary	Assessment of change in the peak pelvic pain score	The change in peak pelvic pain score using an 11-point numeric rating scale (NRS, scale ranging from 0 (no symptom) to 10 (extreme severity of symptom) of the dysmenorrhea daily diary (DysDD) assessments) from cramping window of Cycle 5 to cramping window of Cycle 6 will be analyzed.	At the cramping windows of Cycles No. 5 and 6 (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary	Assessment of relative change in the peak pelvic pain score	The relative change in peak pelvic pain score using an 11-point numeric rating scale (NRS, scale ranging from 0 (no symptom) to 10 (extreme severity of symptom) of the dysmenorrhea daily diary (DysDD) assessments) from cramping window of Cycle 5 to cramping window of Cycle 6 will be analyzed.	At the cramping window of Cycles No. 5 and 6 (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary	Assessment of change in the number of standard pain relief medication taken	The number of standard pain relief medication will be calculated as sum of tablets/capsules taken during the cramping window. The change from cramping window of Cycle 5 to cramping window of Cycle 6 will be analyzed.	At the cramping window of Cycles No. 5 and 6 (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).
Secondary	Assessment of relative change in the number of standard pain relief medication taken	The number of standard pain relief medication will be calculated as sum of tablets/capsules taken during the cramping window. The relative change from cramping window of Cycle 5 to cramping window of Cycle 6 will be analyzed.	At the cramping window of Cycles No. 5 and 6 (each cycle is 28 days). The cramping window is defined as Days -1 to 3 of a menstrual cycle (i.e., 4 days in total).